IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ANTEROGEN CO., LTD. Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.	South Korea	065660
Antibiotice S.A. Develops and manufactures generic medicines and APIs, specializing in anti-infectives.	Romania	ATB
Apellis Pharmaceuticals, Inc. Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.	United States of America	APLS
Apimeds Pharmaceuticals US, Inc. Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.	United States of America	APUS
Apogee Therapeutics, Inc. Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.	United States of America	APGE
Apollomics Inc. A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.	United States of America	APLM
Apontis Pharma AG German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.	Germany	APPH
APPLIED DNA SCIENCES INC Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.	United States of America	APDN
Applied Therapeutics, Inc. Develops treatments for rare metabolic and central nervous system (CNS) disorders.	United States of America	APLT
Aprea Therapeutics, Inc. Developing precision cancer therapies targeting DNA Damage Response for solid tumors.	United States of America	APRE